



(11) **EP 3 199 172 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

(15) Correction information:
Corrected version no 1 (W1 A1)
Corrections, see
Bibliography INID code(s) 84

(51) Int Cl.:
A61K 38/02 ^(2006.01) **A61K 38/16** ^(2006.01)
A61P 25/28 ^(2006.01) **A61K 38/07** ^(2006.01)
A61K 9/00 ^(2006.01) **A61K 31/785** ^(2006.01)

(48) Corrigendum issued on:
11.10.2017 Bulletin 2017/41

(43) Date of publication:
02.08.2017 Bulletin 2017/31

(21) Application number: **17157735.6**

(22) Date of filing: **19.08.2010**

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NO PL
PT RO SE SI SK SM TR
Designated Extension States:
BA ME RS

(30) Priority: **20.08.2009 US 274687 P**
11.02.2010 US 337612 P

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
17153450.6
13166080.5 / 2 630 962
10810282.3 / 2 405 749

(71) Applicant: **Yeda Research and Development Co.,
Ltd.**
76100 Rehovot (IL)

(72) Inventor: **KLINGER, Ety**
39930 Tel Aviv (IL)

(74) Representative: **D Young & Co LLP**
120 Holborn
London EC1N 2DY (GB)

Remarks:

This application was filed on 23-02-2017 as a
divisional application to the application mentioned
under INID code 62.

(54) **DOSING REGIMEN FOR MULTIPLE SCLEROSIS**

(57) A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human

patient three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient.

EP 3 199 172 A8